ETCTN Trials by Disease/ Treatment Area: Gynecologic Cancer

Gynecologic Cancer

- Cervical/vaginal
  - 10132: A Phase I Study of the Wee 1 Kinase (Wee 1) Inhibitor AZD1775 in Combination with Radiotherapy and Cisplatin in Cervical, Upper Vaginal and Uterine Cancers

- Endometrial
  - 9892: Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination with Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer
  - 10104: A Randomized Phase 2 Study of Cabozantinib in Combination with Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer (Exploratory cohort eligibility: Endometrial carcinosarcoma only)

- Ovarian
  - 10017: A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian Cancer
  - 9948: Phase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine with or without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer
  - 10150: A Randomized Phase 2 Study of Bevacizumab and Either Weekly Atezolizumab Radvansine or Weekly Paclitaxel in Platinum Resistant or Platinum Refractory Ovarian Cancer

- Uterine sarcoma
  - ▼ 9676: A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients with Advanced Solid Tumors (Expansion phase, Pt. 1 includes melanoma, renal cell, ovarian, and colorectal cancer)
  - 10324: A Phase I/II Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) with M3814 in Platinum-Resistant or Ineligible Ovarian and Related Cancers with Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)
  - 10250: A Phase II Study of the PARP Inhibitor Olaparib in Combination with the DNA Damaging Agent Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma

NOTE: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: January 15, 2020